Country Meadows Nursing Center Of Bethlehem in Bethlehem, PA

Country Meadows Nursing Center Of Bethlehem is a medicare and medicaid certified nursing home in Bethlehem, Pennsylvania. It is located in Northampton county at 4025 Green Pond Road, Bethlehem, Pennsylvania 18020. You can reach out to the office of Country Meadows Nursing Center Of Bethlehem via phone at (610) 882-4110. This skilled nursing facility has 70 federally certified beds with average occupancy rate of 55%. The nursing facility is classified as "Continuing Care Retirement Community" by CMS and its legal business name is Country Meadows Of Northampton Associates Lp and has the following ownership type - For Profit - Corporation.

Country Meadows Nursing Center Of Bethlehem (Medicare CCN 396053) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 1998 (26 years certified) and the last quality survey was conducted in September, 2020.

Contact Information

Country Meadows Nursing Center Of Bethlehem
4025 Green Pond Road, Bethlehem, Pennsylvania 18020
(610) 882-4110


Nursing Home Profile

NameCountry Meadows Nursing Center Of Bethlehem
Location4025 Green Pond Road, Bethlehem, Pennsylvania
Certified ByMedicare and Medicaid
No. of Certified Beds70
Occupancy Rate55%
Medicare ID (CCN)396053
Legal Business NameCountry Meadows Of Northampton Associates Lp
Ownership TypeFor Profit - Corporation

NPI Associated with this Nursing Home:

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Country Meadows Nursing Center Of Bethlehem from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1265432165
Organization NameCOUNTRY MEADOWS OF NORTHAMPTON ASSOCIATES, LP
Doing Business AsCOUNTRY MEADOWS NURSING CENTER OF BETHLEHEM
Address4025 Green Pond Rd, Bethlehem, PA 18020
Phone Number610-882-4110

News Archive

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

FM market for healthcare in Australia expected to grow at annual rate of 3.1%, finds new analysis

In 2012, the public healthcare sector in Australia was more than twice the size of the private healthcare sector in terms of hospital beds and total hospital expenditure. While private healthcare and other small to medium medical facilities do provide facilities management opportunities, it is mostly to small and medium FM companies. The larger and well-established FM providers will mostly come into play with the successful implementation of public private partnerships model in the healthcare sector.

Austrian patent office rules in Pfizer's Favor for Lipitor patent

Pfizer has announced that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy.

No added benefit from retigabine therapy in adults with epileptic seizures

The drug retigabine was approved in March 2011 as add-on therapy for adults with epileptic seizures. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether retigabine offers an added benefit compared with the present standard therapy.

Findings explain molecular mechanisms underlying microvascular disease in diabetes patients

Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail to heal properly, which can lead to ulcers, chronic infections, and in the most serious cases, limb amputations.

Read more Medical News

› Verified 7 days ago


NPI Number1366737116
Organization NameGENESIS
Address4025 Green Pond Rd, Bethlehem, PA 18017
Phone Number610-882-4110

News Archive

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

FM market for healthcare in Australia expected to grow at annual rate of 3.1%, finds new analysis

In 2012, the public healthcare sector in Australia was more than twice the size of the private healthcare sector in terms of hospital beds and total hospital expenditure. While private healthcare and other small to medium medical facilities do provide facilities management opportunities, it is mostly to small and medium FM companies. The larger and well-established FM providers will mostly come into play with the successful implementation of public private partnerships model in the healthcare sector.

Austrian patent office rules in Pfizer's Favor for Lipitor patent

Pfizer has announced that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy.

No added benefit from retigabine therapy in adults with epileptic seizures

The drug retigabine was approved in March 2011 as add-on therapy for adults with epileptic seizures. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether retigabine offers an added benefit compared with the present standard therapy.

Findings explain molecular mechanisms underlying microvascular disease in diabetes patients

Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail to heal properly, which can lead to ulcers, chronic infections, and in the most serious cases, limb amputations.

Read more Medical News

› Verified 7 days ago

Quality Ratings:

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Country Meadows Nursing Center Of Bethlehem are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Country Meadows Nursing Center Of Bethlehem give to their patients.
Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

FM market for healthcare in Australia expected to grow at annual rate of 3.1%, finds new analysis

In 2012, the public healthcare sector in Australia was more than twice the size of the private healthcare sector in terms of hospital beds and total hospital expenditure. While private healthcare and other small to medium medical facilities do provide facilities management opportunities, it is mostly to small and medium FM companies. The larger and well-established FM providers will mostly come into play with the successful implementation of public private partnerships model in the healthcare sector.

Austrian patent office rules in Pfizer's Favor for Lipitor patent

Pfizer has announced that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy.

No added benefit from retigabine therapy in adults with epileptic seizures

The drug retigabine was approved in March 2011 as add-on therapy for adults with epileptic seizures. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether retigabine offers an added benefit compared with the present standard therapy.

Findings explain molecular mechanisms underlying microvascular disease in diabetes patients

Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail to heal properly, which can lead to ulcers, chronic infections, and in the most serious cases, limb amputations.

Read more Medical News

› Verified 7 days ago

Complaints, Fines and Penalties:

Number of Facility Reported Incidents0
Number of Substantiated Complaints0
Number of Fines0
Total Amount of Fines in Dollars$0
Number of Payment Denials0
Total Number of Penalties0

Patients' Stay Experience:

The resident survey data of Country Meadows Nursing Center Of Bethlehem is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience MeasureProviderNational Avg.
Percentage of long-stay residents whose need for help with daily activities has increased14.2914.46
Percentage of long-stay residents who lose too much weight20.295.51